title: Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants.
abstract: OBJECTIVE
  Aberrant survivin expression in cancer cells has been associated with tumour progression, radiation/drug resistance and shorter patient survival. The aim of the present study was to investigate survivin expression in laryngeal carcinoma (LSCC) tissue and - for the first time at this site - the expression of survivin splice variants. P53 was also studied.
  
  
  RESULTS
  Survivin and p53 expression was determined immunohistochemically in 86 consecutive patients operated for LSCC. Survivin mRNA expression was assessed by quantitative real-time polymerase chain reaction (PCR). Hot-spot mutations in exons 5, 6, 7 and 8 of the TP53 gene were studied by sequencing analysis. A nuclear localization for survivin predominated. There was a significant association between a higher nuclear survivin expression and LSCC recurrence (P = 0.046). Disease-free survival (DFS) for LSCC patients with a nuclear survivin expression >7.0% was shorter than in cases whose expression was ≤7.0% (P = 0.05). Wild-type survivin correlated significantly with nuclear survivin expression (P = 0.02). p53 expression was associated with the co-expression of wild-type survivin and survivin-2B (P = 0.01).
  
  
  CONCLUSIONS
  Nuclear expression of survivin appears to influence LSCC aggressiveness, a higher nuclear survivin expression correlating with a higher recurrence rate and a shorter DFS. Wild-type survivin was the most frequently detected splice variant in LSCC tissues.
authors.affiliation: Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy. gino.marioni@unipd.it
authors.forename: Gino
authors.initials: G
authors.lastname: Marioni
authors.forename: Marco
authors.initials: M
authors.lastname: Agostini
authors.forename: Chiara
authors.initials: C
authors.lastname: Bedin
authors.forename: Stella
authors.initials: S
authors.lastname: Blandamura
authors.forename: Edoardo
authors.initials: E
authors.lastname: Stellini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Favero
authors.forename: Marco
authors.initials: M
authors.lastname: Lionello
authors.forename: Luciano
authors.initials: L
authors.lastname: Giacomelli
authors.forename: Silvia
authors.initials: S
authors.lastname: Burti
authors.forename: Edoardo
authors.initials: E
authors.lastname: D'Angelo
authors.forename: Donato
authors.initials: D
authors.lastname: Nitti
authors.forename: Alberto
authors.initials: A
authors.lastname: Staffieri
authors.forename: Cosimo
authors.initials: C
authors.lastname: De Filippis
mesh_terms: D000368:Aged; D017398:Alternative Splicing; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D016158:Genes, p53; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics* / Q000378:metabolism*; D007822:Laryngeal Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D000077022:Survivin; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D000077022:Survivin; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53